Recent News

• 06.03.2026 - Cadrenal Therapeutics to Showcase Phase 3-Ready CAD-1005 and Novel 12-LOX Platform at BIO International Convention 2026 Partnering Event
• 05.19.2026 - Cadrenal Therapeutics to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026
• 05.07.2026 - Cadrenal Therapeutics Reports First Quarter 2026 Financial Results and Provides Phase 3 Development Update on CAD-1005 Following End-of-Phase 2 Meeting with FDA
• 04.30.2026 - Cadrenal Therapeutics Announces End-of-Phase 2 Meeting with the FDA and Pivotal Phase 3 Registration Path for CAD-1005 in Heparin-Induced Thrombocytopenia (HIT)

Recent Filings

• 06.02.2026 - 4 Statement of changes in beneficial ownership of securities
• 05.29.2026 - 4 Statement of changes in beneficial ownership of securities
• 05.26.2026 - 4 Statement of changes in beneficial ownership of securities
• 05.11.2026 - 144 Report of proposed sale of securities
• 05.07.2026 - EX-99.1 EX-99.1
• 05.07.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 05.07.2026 - 8-K Current report
• 04.30.2026 - 8-K Current report
• 04.30.2026 - EX-99.1 EX-99.1
• 04.29.2026 - 424B3 Prospectus [Rule 424(b)(3)]